Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.
Rita Levi Montalcini' Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy.
Sci Rep. 2019 Apr 11;9(1):5931. doi: 10.1038/s41598-019-42091-3.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects 1 in ~350 individuals. Genetic association studies have established ALS as a multifactorial disease with heritability estimated at ~61%, and recent studies show a prominent role for rare variation in its genetic architecture. To identify rare variants associated with disease onset we performed exome array genotyping in 4,244 cases and 3,106 controls from European cohorts. In this largest exome-wide study of rare variants in ALS to date, we performed single-variant association testing, gene-based burden, and exome-wide individual set-unique burden (ISUB) testing to identify single or aggregated rare variation that modifies disease risk. In single-variant testing no variants reached exome-wide significance, likely due to limited statistical power. Gene-based burden testing of rare non-synonymous and loss-of-function variants showed NEK1 as the top associated gene. ISUB analysis did not show an increased exome-wide burden of deleterious variants in patients, possibly suggesting a more region-specific role for rare variation. Complete summary statistics are released publicly. This study did not implicate new risk loci, emphasizing the immediate need for future large-scale collaborations in ALS that will expand available sample sizes, increase genome coverage, and improve our ability to detect rare variants associated to ALS.
肌萎缩侧索硬化症(ALS)是一种致命的神经退行性疾病,影响约 350 个人中的 1 个。遗传关联研究将 ALS 确立为一种多因素疾病,遗传率估计约为 61%,最近的研究表明罕见变异在其遗传结构中起着突出作用。为了确定与疾病发作相关的罕见变异,我们对来自欧洲队列的 4244 例病例和 3106 例对照进行了外显子组基因分型。在迄今为止对 ALS 罕见变异进行的最大外显子组研究中,我们进行了单变异关联测试、基于基因的负担测试和外显子组个体独特集合负担(ISUB)测试,以识别改变疾病风险的单个或聚集的罕见变异。在单变异测试中,没有变异达到外显子组全基因组显著水平,这可能是由于统计效力有限。罕见非同义变异和功能丧失变异的基于基因的负担测试表明 NEK1 是最相关的基因。ISUB 分析并未显示患者中有害变异的外显子组全基因组负担增加,这可能表明罕见变异的作用更具区域特异性。完整的汇总统计数据已公开发布。这项研究没有暗示新的风险基因座,这强调了肌萎缩侧索硬化症未来需要进行大规模的合作研究,以扩大现有样本量、增加基因组覆盖范围,并提高我们检测与肌萎缩侧索硬化症相关的罕见变异的能力。